SCHEMBL103875

SCHEMBL103875

Cc1cnc2cc(F)c(F)cc2n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
PDGFRB P09619 4/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
PDGFRA P16234 3/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
CYP11B2 P19099 8/20 0.36
CYP11B1 P15538 5/20 0.36
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20049244 0.90 ALDH1A1 (0.47) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2
SCHEMBL21225653 0.86 ALDH1A1 (0.44) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2
SCHEMBL21225611 0.86 ALDH1A1 (0.44) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2
SCHEMBL24140225 0.85 ALDH1A1 (0.48) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2
SCHEMBL24338007 0.83 ILK (0.39) ALDH1A1RAB9ASMN1; SMN2CCNB2CDK1
SCHEMBL2679771 0.81 ALDH1A1 (0.61) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2
SCHEMBL29639032 0.81 ALDH1A1 (0.61) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2
SCHEMBL24339324 0.80 KDM4E (0.45) ALDH1A1SMN1; SMN2CYP1A2HTT
SCHEMBL29639044 0.77 ALDH1A1 (0.52) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2
SCHEMBL29639037 0.77 ALDH1A1 (0.42) ALDH1A1PDGFRBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116410146-A One-step process for converting polyols to nitrogen-containing heterocycles using heterogeneous metal catalysts 浙江大学 2023-07-11 CN disclosed
CN-113087674-B Method for synthesizing quinoxaline compound under catalysis of visible light induced photosensitizer 河南大学 2022-06-17 CN disclosed
CN-113087674-A Method for synthesizing quinoxaline compound under visible light induced iron catalysis condition 河南大学 2021-07-09 CN disclosed
WO-2019152731-A1 ANDROGEN RECEPTOR ANTAGONISTS ALPINE ANDROSCIENCES, INC. (US) 2019-08-08 WO disclosed
US-8883826-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-11-11 US disclosed
US-8674106-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-03-18 US disclosed
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-07-11 US disclosed
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2012-11-01 US disclosed
EP-2426115-A2 Alkynyl derivatives as modulators of metabotropic glutamate receptors Addex Pharma SA (CH) 2012-03-07 EP disclosed
US-8101637-B2 Alkynyl derivatives as modulators of metatropic glutamate receptors ADDEX PHARMA SA (CH) 2012-01-24 US disclosed
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2009-05-14 US disclosed
EP-1385845-B1 N-AROYL CYCLIC AMINES SMITHKLINE BEECHAM PLC (GB) 2008-01-09 EP disclosed
EP-1765795-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharmaceuticals SA (CH) 2007-03-28 EP disclosed
WO-2005123703-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2005-12-29 WO disclosed
WO-2004041807-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-05-21 WO disclosed
WO-2004041791-A1 N-ARYL ACETYL CYCLIC AMINE DERIVATIVES AS OREXIN ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 ALDH1A1 2153/4885PDGFRB 1419/4885NPC1 949/4885
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS GRM5, GRM2, GRM1 ALDH1A1 2496/4885PDGFRB 1717/4885NPC1 817/4885
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 ALDH1A1 2153/4885PDGFRB 1419/4885NPC1 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.